Alembic Pharmaceuticals share price

Balanced risk
  • 39%Low risk
  • 39%Moderate risk
  • 39%Balanced risk
  • 39%High risk
  • 39%Extreme risk
  • 937.80(-0.30%)
    June 23, 2025 15:29:39 PM IST
    • NSE
    • BSE
  • Vol : 143.09K (NSE + BSE)
    Last 20 day avg : 93.23 K

Alembic Pharmaceuticals is trading -0.30% lower at Rs 937.80 as compared to its last closing price. Alembic Pharmaceuticals has been trading in the price range of 946.55 & 923.15. Alembic Pharmaceuticals has given -12.34% in this year & -6.45% in the last 5 days. Alembic Pharmaceuticals has TTM P/E ratio 31.32 as compared to the sector P/E of 22.54.There are 11 analysts who have initiated coverage on Alembic Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 156.87 Crores in its last quarter.Listed peers of Alembic Pharmaceuticals include Syngene International (0.65%), Eris Lifesciences (-0.25%), Alembic Pharmaceuticals (-0.30%).The Mutual Fund holding in Alembic Pharmaceuticals was at 9.20% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Alembic Pharmaceuticals was at 3.94% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Jun 23, 2025, 10:45 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    1.18
    Higher than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.54
    In line with historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    31.48
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.71
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.24
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
923.15
Highest
946.55
52 week range
Lowest
725.60
Highest
1,296.15
Alembic Pharmaceuticals Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 16.65% from Rs 1769.63 crore to Rs 1516.98 crore, year-on-year
    • financial-insightsThe company's profit declined by 11.97% year-on-year during the March quarter, dropping from Rs 178.21 crore to Rs 156.87 crore
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Alembic Pharmaceuticals Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,063.87
  • R2
  • 1,110.53
  • R3
  • 1,180.82
Pivot993.58
  • S1
  • 946.92
  • S2
  • 876.63
  • S3
  • 829.97
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Alembic Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Syngene International
Bearish
636.050.6525,698.6753.765.360.208.65
Eris Lifesciences
Neutral
1,620.00-0.2522,129.6463.027.760.4562.42
Alembic Pharmaceuticals
Neutral
937.80-0.3018,453.4932.223.541.180.90
Jubilant Pharmova
Neutral
1,123.151.3117,924.6633.032.810.4538.19
Natco Pharma
Bearish
867.95-0.8415,545.848.312.060.690.06
Alembic Pharmaceuticals Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Alembic Pharmaceuticals is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 69.67%
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.23 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.24 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    DSP Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 145.40
    • % of AUM 4.91
    Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 24.47
    • % of AUM 3.00
    Kotak Small Cap Growth
    3/5
    • Amount Invested (Cr.) 348.97
    • % of AUM 2.01
    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
    NA
    • Amount Invested (Cr.) 109.38
    • % of AUM 1.99
    DSP Midcap Fund Growth
    2/5
    • Amount Invested (Cr.) 301.46
    • % of AUM 1.61
    Alembic Pharmaceuticals Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-06Audited Results & Final Dividend
    2025-02-03Quarterly Results & Others
    2024-11-07Quarterly Results
    2024-08-08Quarterly Results
    2024-05-09Audited Results & Final Dividend
    About the company Alembic Pharmaceuticals
    • IndustryBiotechnology & Drugs
    • ISININE901L01018
    • BSE Code533573
    • NSE CodeAPLLTD
    Alembic Pharmaceuticals Limited is an India-based diversified pharmaceutical company. The Company is engaged in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Labs LLC and others.
    • Management Info
    • Chirayu AminExecutive Chairman of the Board, Chief Executive Officer
    • Raj BahetiChief Financial Officer, Director - Finance, Executive Director
    • Manisha SarafCompliance Officer, Company Secretary
    • Pranav AminManaging Director, Executive Director
    • Shaunak AminManaging Director, Executive Director
    Alembic Pharmaceuticals Share Price FAQs

    Alembic Pharmaceuticals is trading at 937.80 as on Mon Jun 23 2025 09:59:39. This is -0.30% lower as compared to its previous closing price of 940.65.

    The market capitalization of Alembic Pharmaceuticals is 18453.49 Cr as on Mon Jun 23 2025 09:59:39.

    The average broker rating on Alembic Pharmaceuticals is Buy. The breakup of analyst rating is given below -

    • 3 analysts have given a strong buy rating
    • 2 analysts have given a buy rating
    • 5 analysts have given a hold rating
    • 0.00 analysts have given a sell rating
    • 1 analysts have given a strong sell rating

    The 52 wk high for Alembic Pharmaceuticals is 1296.15 whereas the 52 wk low is 725.60

    Alembic Pharmaceuticals can be analyzed on the following key metrics -

    • TTM P/E: 31.32
    • Sector P/E: 22.54
    • Dividend Yield: 1.18%
    • D/E ratio: 0.24

    Alembic Pharmaceuticals reported a net profit of 583.42 Cr in 2025.

    The Mutual Fund Shareholding was 9.20% at the end of 31 Mar 2025.